natgillin/translations-raw huggingface dataset:
- The active substance is memantine hydrochloride. 
Zdravilna učinkovina je memantinijev klorid.
Memantine Accord contains the active substance memantine hydrochloride. 
Zdravilo Memantin Accord vsebuje zdravilno učinkovino memantinijev klorid.
Maintenance dose The recommended maintenance dose is 20 mg per day. 
Vzdrževalni odmerek Priporočeni odmerek je 20 mg na dan.
Film-coated tablets. 
50 filmsko obloženih tablet.
Elevated liver function test Not known Hepatitis 
Bolezni jeter, žolčnika in žolčevodov Pogosti Neznane pogostnosti zvišani jetrni funkcijski testi hepatitis
Hepatic impairment 
Glavobol Utrujenost
How to take Memantine Accord 
Kako jemati zdravilo Memantin Accord
Take one 20 mg tablet per day (pale red to greyred, scored) for 7 days. 
Eno 20 mg filmsko obloženo tableto na dan (bledo rdeča do sivo rdeča z razdelilno zarezo) jemljite 7 dni.
Memantine Accord 20 mg film-coated tablets 
Memantin Accord 20 mg filmsko obložene tablete
Excipientwith known effect: each film-coated tablet contains 73.80 mg lactose (as monohydrate). 
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 73,80 mg laktoze (v obliki monohidrata).
Memantine Accord acts on these NMDA-receptors improving the transmission of nerve signals and the memory. 
Memantin Accord spada v skupino zdravil, ki se imenujejo antagonisti receptorjev NMDA. Memantin Accord deluje na receptorje NMDA in izboljša prenos živčnih signalov in spomin.
Memantine Accord 10 mg film-coated tablets 
Memantin Accord 10 mg filmsko obložene tablete
Tablet cores for 5/10/15/20 mg film-coated tablets Lactose monohydrate 
Jedro tablete pri 5/10/15/20 mg filmsko obloženih tabletah laktoza monohidrat mikrokristalna celuloza brezvodni koloidni silicijev dioksid krospovidon magnezijev stearat
Excipientwith known effect: each film-coated tablet contains 295.18 mg lactose (as monohydrate). 
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 295,18 mg laktoze (v obliki monohidrata).
How does Memantine Accord work 
Kako deluje zdravilo Memantin Accord
Hypromellose Polysorbate 80 Macrogol 400 
Obloga tablete hipromeloza polisorbat 80 makrogol 400 titanov dioksid (E 171)
Memantine Accord 5 mg film-coated tablets Memantine Accord 10 mg film-coated tablets Memantine Accord 15 mg film-coated tablets Memantine Accord 20 mg film-coated tablets 
Memantin Accord 5 mg filmsko obložene tablete Memantin Accord 10 mg filmsko obložene tablete Memantin Accord 15 mg filmsko obložene tablete Memantin Accord 20 mg filmsko obložene tablete
Each film-coated tablet contains 5 mg memantine hydrochloride equivalent to 4.15 mg memantine. 
Ena filmsko obložena tableta vsebuje 5 mg memantinijevega klorida, kar ustreza 4,15 mg memantina.
What Memantine Accord contains 
Kaj vsebuje zdravilo Memantin Accord
Memantine Accord 20 mg tablets are also available in perforated unit dose calendar blister in packsizes of 14x1, 28x1, 56x1 or 98x1 tablet. 
Memantin Accord 20 mg filmsko obložene tablete so na voljo tudi v obliki perforiranega pretisnega omota za enkratno uporabo z natisnjenim koledarjem, v pakiranjih po 14 x 1, 28 x 1, 56 x 1 ali 98 x 1 tableta.
NAME OF THE MEDICINAL PRODUCT Memantine Accord 10 mg film-coated tablets memantine hydrochloride 
IME ZDRAVILA Memantin Accord 10 mg filmsko obložene tablete memantinijev klorid
Memantine Accord 5 mg film-coated tablets Memantine Accord 10 mg film-coated tablets Memantine Accord 15 mg film-coated tablets Memantine Accord 20 mg film-coated tablets memantine hydrochloride 
Memantin Accord 5 mg filmsko obložene tablete Memantin Accord 10 mg filmsko obložene tablete Memantin Accord 15 mg filmsko obložene tablete Memantin Accord 20 mg filmsko obložene tablete memantinijev klorid
The 15 mg film-coated tablets are orange to grey-orange, oblong, coated tablets debossedwith "MT" on one side and "15" on the other side. 
15 mg filmsko obložene tablete so oranžne do sivo oranžne, podolgovate, obložene tablete z vtisnjeno oznako "MT" na eni strani in vtisnjeno številko "15" na drugi strani.
Excipientwith known effect: each film coated tablet contains 183.13 mg lactose (as monohydrate). 
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 183,13 mg laktoze (v obliki monohidrata).
Memantine Accord film-coated tablets are also available in perforated unit dose calendar blister in pack-sizes of 14x1, 28x1, 56x1 or 98x1 tablet. 
Memantin Accord filmsko obložene tablete so na voljo tudi v obliki perforiranega pretisnega omota za enkratno uporabo z natisnjenim koledarjem, v pakiranjih po 14 x 1, 28 x 1, 56 x 1 ali 98 x 1 tableta.
Memantine Accord 10 mg tablets are also available in perforated unit dose calendar blister in pack-sizes of 14x1, 28x1, 56x1 or 98x1 tablet. 
Memantin Accord 10 mg filmsko obložene tablete so na voljo tudi v obliki perforiranega pretisnega omota za enkratno uporabo z natisnjenim koledarjem, v pakiranjih po 14 x 1, 28 x 1, 56 x 1 ali 98 x 1 tableta.
Each film-coated tablet contains 15 mg memantine hydrochloride equivalent to 12.46 mg memantine. 
Ena filmsko obložena tableta vsebuje 15 mg memantinijevega klorida, kar ustreza 12,46 mg memantina.
Week 3 (day 15-21): The patient should take one 15 mg film-coated tablet per day (orange to grey-orange) for 7 days. 
3. teden (15.-21. dan): Bolnik naj 7 dni jemlje eno 15 mg filmsko obloženo tableto na dan (oranžna do sivo oranžna).
Each film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine - The other ingredients are lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate, all in the tablet core; hypromellose, polysorbate 80, macrogol 400, titanium dioxide (E 171), iron oxide red (E 172), iron oxide yellow (E 172) all in the tablet coating 
mikrokristalna celuloza, brezvoden koloidni silicijev dioksid, krospovidon in magnezijev stearat, vse v jedru tablete; in hipromeloza, polisorbat 80, makrogol 400, titanov dioksid (E 171), rdeči železov dioksid (E 172) in rumeni železov oksid (E 172) vse v oblogi tablete.
Each film-coated tablet contains 10 mg of memantine hydrochloride equivalent to 8.31 mg memantine - The other ingredients are lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate, all in the tablet core; hypromellose, polysorbate 80, macrogol 400, titanium dioxide (E 171), all in the tablet coating 
Pomožne snovi so: laktoza monohidrat, mikrokristalna celuloza, brezvoden koloidni silicijev dioksid, krospovidon, magnezijev stearat, vse v jedru tablete; hipromeloza, polisorbat 80, makrogol 400, titanov dioksid (E 171), vse v oblogi tablete.
Week 2 (day 8-14): The patient should take one 10 mg film-coated tablet per day (white, scored) for 7 days. 
2. teden (8.-14. dan): Bolnik naj 7 dni jemlje eno 10 mg filmsko obloženo tableto na dan (bela z razdelilno zarezo).
EU/1/13/880/016 14 x 1 film-coated tablets EU/1/13/880/017 28 x 1 film-coated tablets EU/1/13/880/018 56 x 1film-coated tablets EU/1/13/880/019 98 x 1film-coated tablets 
EU/1/13/880/016 14 x 1 filmsko obložena tableta EU/1/13/880/017 28 x 1 filmsko obložena tableta EU/1/13/880/018 56 x 1 filmsko obložena tableta EU/1/13/880/019 98 x 1 filmsko obložena tableta
EU/1/13/880/020 14 x 1 film-coated tablets EU/1/13/880/021 28 x 1 film-coated tablets EU/1/13/880/022 56 x 1 film-coated tablets EU/1/13/880/023 98 x 1 film-coated tablets 
EU/1/13/880/020 14 x 1 filmsko obložena tableta EU/1/13/880/021 28 x 1 filmsko obložena tableta EU/1/13/880/022 56 x 1 filmsko obložena tableta EU/1/13/880/023 98 x 1 filmsko obložena tableta
Memantine Accord 20 mg film-coated tablets memantine hydrochloride 
Memantin Accord 20 mg filmsko obložene tablete memantinijev klorid
The 20 mg film-coated tablets are pale red to grey-red, oblong, scored, coated tablets, debossed with "MT" divided by the score on one side and "20" divided by the score on the other side. 
20 mg filmsko obložene tablete so bledo rdeče do sivo rdeče, podolgovate obložene tablete z razdelilno zarezo z vtisnjeno oznako "MT" na eni strani zareze in vtisnjeno številko "20" na drugi strani zareze.
The patient should take one 15 mg film-coated tablet per day for 7 days. 
Bolnik naj sedem dni jemlje eno 15 mg filmsko obloženo tableto na dan. Od 4. tedna dalje
Memantine Accord 10 mg film-coated tablets memantine hydrochloride 
Memantin Accord 10 mg filmsko obložene tablete memantinijev klorid
Contents of the pack and other information What Memantine Accord contains - The active substance is memantine hydrochloride. 
Kaj vsebuje zdravilo Memantin Accord Zdravilna učinkovina je memantinijev klorid.
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p = 0.025; Alzheimer´s disease cooperative study - activities of daily living (ADCS-ADLsev): p = 0.003; severe impairment battery (SIB): p = 0.002). 
V temeljni klinični študiji pri skupini 252 bolnikov z zmerno do hudo Alzheimerjevo boleznijo (314točk na lestvici Kratkega preskusa spoznavnih sposobnosti (KPSS oz. MMSE ali "Mini-mental State Examination")) ob vključitvi je zdravljenje z memantinom v monoterapiji pokazalo izboljšanje v primerjavi s placebom, v obdobju 6 mesečnega zdravljenja (analiza opazovanih bolnikov, lestvice Vtis sprememb na osnovi kliničnega intervjuja (CIBIC-plus - "Clinician's Interview-Based Impression of Change Plus Caregiver Input"): p = 0,025; Vprašalnik vsakodnevnih aktivnosti (ADCS-ADLsev oz.
The 5 mg film-coated tablets are white, oblong, coated tablets, debossed with "MT" on one side and "5" on the other side. 
5 mg filmsko obložene tablete so bele, podolgovate obložene tablete z vtisnjeno oznako "MT" na eni strani in vtisnjeno številko "5" na drugi strani.
Each film-coated tablet contains 5/10/15/20 mg of memantine hydrochloride equivalent to 4.15/8.31/12.46/16.62 mg memantine - The other ingredients are lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate, all in the tablet core; hypromellose, polysorbate 80, macrogol 400, titanium dioxide (E 171), and additional for Memantine Accord 15 mg and Memantine Accord 20 mg film-coated tablets iron oxide yellow and red (E 172), all in the tablet coating 
Pomožne snovi so: laktoza monohidrat, mikrokristalna celuloza, brezvoden koloidni silicijev dioksid, krospovidon, magnezijev stearat, vse v jedru tablete; in hipromeloza, polisorbat 80, makrogol 400, titanov dioksid (E 171) ter dodatno pri zdravilu Memantin Accord 15 mg filmsko obležene tablete in pri zdravilu.
Memantine Accord 15 mg film-coated tablets are presented as orange to grey-orange, oblong, coated tablet, debossed with “MT” on one side and “15” on the other side. 
Memantin Accord 15 mg filmsko obložene tablete so oranžne do sivo oranžne, ovalne obložene tablete z vtisnjeno oznako "MT" na eni strani in vtisnjeno številko "15" na drugi strani.
The patient should take one 10 mg film-coated tablet per day for 7 days. 
Bolnik naj sedem dni jemlje eno in pol 10 mg filmsko obloženo tableto (15 mg) na dan.
Memantine Accord 10 mg film-coated tablets are presented as white, oblong, coated and scored tablet, debossed with “MT” divided by the score on one side and “10” divided by the score on the other side. 
Memantin Accord 10 mg filmsko obložene tablete so bele, ovalne, obložene tablete z razdelilno zarezo in vtisnjeno oznako "MT" na eni strani zareze in vtisnjeno številko "10" na drugi strani zareze.
Each pack with 28 film-coated tablets for a 4 week treatment schedule contains: 7 x Memantine Accord 5 mg 
Vsako pakiranje z 28 filmsko obloženimi tabletami za štiri tedne trajajočo shemo zdravljenja.
The 10 mg film-coated tablets are white, oblong, coated and scored tablets, debossed with "MT" divided by the score on one side and "10" divided by the score on the other side. 
10 mg filmsko obložene tablete so bele, podolgovate obložene tablete z razdelilno zarezo z vtisnjeno oznako "MT" na eni strani zareze in vtisnjeno številko "10" na drugi strani zareze.
Memantine Accord 5 mg film-coated tablets are presented as white, oblong, coated tablet, debossed with “MT” on one side and “5” on the other side. 
Memantin Accord 5 mg filmsko obložene tablete so bele, ovalne obložene tablete z vtisnjeno oznako "MT" na eni strani in vtisnjeno številko "5" na drugi strani.
Week 1 (day 1-7): The patient should take one 5 mg film-coated tablet per day (white) for 7 days. 
1. teden (1.-7. dan): Bolnik naj 7 dni jemlje eno 5 mg filmsko obloženo tableto na dan (bela).
Memantine Accord 20 mg film-coated tablets are presented as pale red to greyred, oblong, coated and scored tablet, debossed with “MT” divided by the score on one side and “20” divided by the score on the other side. 
Memantin Accord 20 mg filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalne obložene tablete z razdelilno zarezo z vtisnjeno oznako "MT" na eni strani zareze in vtisnjeno številko "20" na drugi strani zareze.
EU/1/13/880/009 28 fim-coated tablets EU/1/13/880/010 42 fim-coated tablets EU/1/13/880/011 56 fim-coated tablets EU/1/13/880/012 98 fim-coated tablets EU/1/13/880/015 14 fim-coated tablets 
EU/1/13/880/009 28 filmsko obloženih tablet EU/1/13/880/010 42 filmsko obloženih tablet EU/1/13/880/011 56 filmsko obloženih tablet EU/1/13/880/012 98 filmsko obloženih tablet EU/1/13/880/015 14 filmsko obloženih tablet
Memantine Accord film-coated tablets are presented as white, oblong, coated and scored tablet,debossed with "MT" divided by the score on one side and “10” divided by the score on the other side. 
Memantin Accord filmsko obložene tablete so bele, podolgovate, obložene tablete z razdelilno zarezo in vtisnjeno oznako "MT" na eni strani zareze in vtisnjeno številko "10" na drugi strani zareze.
What is Memantine Accord used for 
Za kaj uporabljamo zdravilo Memantin Accord
Pale red to grey-red, oblong, scored, coated tablet, debossed with “MT” divided by the score on one side and "20" divided by the score on the other side. 
Bledo rdeče do sivo rdeče, podolgovate obložene tablete z razdelilno zarezo z vtisnjeno oznako "MT" na eni strani zareze in vtisnjeno številko "20" na drugi strani zareze.
What is in this leaflet 
Kaj vsebuje navodilo?
The patient should take one 20 mg film-coated tablet per day for 7 days. 
Bolnik naj 7 dni jemlje eno 20 mg filmsko obloženo tableto na dan (bledo rdeča do sivo rdeča z razdelilno zarezo).
Magnesium stearate 
Način jemanja
Iron oxide yellow and red (E 172) 
Obloga tablete hipromeloza polisorbat 80 makrogol 400 titanov dioksid (E 171) rumeni in rdeči železov oksid (E 172)
Memantine Accord film-coated tablets are presented as pale red to greyred, oblong, coated and scored tablet, debossed with "MT" divided by the score on one side and “20” divided by the score on the other side. 
Memantin Accord filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalne obložene tablete z razdelilno zarezo in vtisnjeno oznako "MT" na eni strani zareze in vtisnjeno številko "20" na drugi strani zareze.
This includes any possible side effects not listed in this leaflet.See section 4. 
Seznam neželenih učinkov, prikazan v preglednici
Week 2 (day 8-14): The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days. 
2. teden (8.-14. dan): Bolnik naj sedem dni jemlje eno 10 mg filmsko obloženo tableto na dan.
• Seizures 
• epileptični napadi
White, oblong, coated and scored tablet, debossed with “MT” divided by the score on one side and "10" divided by the score on the other side. 
Bele, podolgovate filmsko obložene tablete, z razdelilno zarezo in vtisnjeno oznako "MT" na eni strani zareze in številko "10" na drugi strani zareze.
NAME OF THE MEDICINAL PRODUCT Memantine Accord 5 mg film-coated tablets 
Memantin Accord 5 mg filmsko obložene tablete.
• prostate cancer, when the cancer does not respond to hormonal treatment. 
• raka prostate, kadar se rak ne odziva na hormonsko zdravljenje.
The full EPAR for Docetaxel Kabi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Docetaxel Kabi je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Docetaxel Kabi is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3). 
Zdravilo Docetaxel Kabi se uporablja le, kadar je število nevtrofilcev (raven vrste belih krvnih celic v krvi) normalno (vsaj 1 500 celic/mm3).
This is a summary of the European public assessment report (EPAR) for Docetaxel Kabi. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Docetaxel Kabi.
Docetaxel blocks the ability of cells to destroy the internal ‘skeleton' that allows them to divide and multiply. 
Docetaksel zavira sposobnost celic, da uničijo notranje „ogrodje“, ki celicam omogoča deljenje in razmnoževanje.
The European Commission granted a marketing authorisation valid throughout the European Union for Docetaxel Kabi on 22 May 2012. 
Evropska komisija je dovoljenje za promet z zdravilom Docetaxel Kabi, veljavno po vsej Evropski uniji, odobrila dne 22. maja 2012.
The company provided data from published literature on docetaxel. 
Družba je predstavila podatke o docetakselu iz objavljene literature.
It is available as a concentrate to be made up into a solution for infusion (drip into a vein). 
Na voljo je v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije v veno).
• non-small-cell lung cancer. 
• nedrobnoceličnega pljučnega raka.
Docetaxel Kabi is given as a one-hour infusion every three weeks. 
Zdravilo Docetaxel Kabi se daje v obliki enourne infuzije vsake tri tedne.
The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated. 
Odmerek, trajanje zdravljenja in njegova souporaba z drugimi zdravili so odvisni od vrste raka, ki se zdravi.
The CHMP concluded that, in accordance with EU requirements, Docetaxel Kabi has been shown to be comparable to Taxotere. 
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Docetaxel Kabi primerljivo z zdravilom Taxotere.
For more information about treatment with Docetaxel Kabi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Docetaxel Kabi preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This means that Docetaxel Kabi is similar to a ‘reference medicine' already authorised in the European Union (EU) called Taxotere. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Taxotere.
Because Docetaxel Kabi is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Docetaxel Kabi generično zdravilo, se šteje, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Docetaxel Kabi is used to treat the following types of cancer: 
Zdravilo Docetaxel Kabi se uporablja za zdravljenje naslednjih vrst raka:
An anti-inflammatory medicine such as dexamethasone should also be given to the patient, starting on the day before the Docetaxel Kabi infusion. 
Bolniku je treba dati tudi protivnetno zdravilo, kot je na primer deksametazon, in sicer dan pred infuzijo zdravila Docetaxel Kabi.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Docetaxel Kabi. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Docetaxel Kabi, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Docetaxel Kabi docetaxel 
Docetaxel Kabi docetaksel
It can also be used with other anticancer medicines (doxorubicin, cyclophosphamide, trastuzumab or capecitabine) in patients who have not yet received any treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated; 
Prav tako se lahko uporablja sočasno z drugimi zdravili proti raku (doksorubicinom, ciklofosfamidom, transtuzumabom ali kapecitabinom) pri bolnikih, ki proti raku še niso prejeli nobenih zdravil ali pri katerih so bile druge oblike zdravljenja neuspešne, odvisno od vrste in stadija raka dojke, ki se zdravi;
What are the benefits and risks of Docetaxel Kabi? 
Kakšne so koristi in tveganja, povezani z zdravilom Docetaxel Kabi?
Docetaxel Kabi is a ‘generic medicine'. 
Docetaxel Kabi je „generično zdravilo“.
Docetaxel Kabi can be used on its own after other treatments have failed. 
Zdravilo Docetaxel Kabi se lahko uporablja kot samostojno zdravilo, kadar druge oblike zdravljenja niso bile uspešne.
Other information about Docetaxel Kabi 
Druge informacije o zdravilu Docetaxel Kabi
Docetaxel Kabi should be used in wards specialising in chemotherapy (using medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy. 
Zdravilo Docetaxel Kabi se sme uporabljati samo na specializiranih oddelkih za kemoterapijo (kjer se uporabljajo zdravila proti raku) in se daje le pod nadzorom zdravnika, usposobljenega za uporabo kemoterapije.
The Committee recommended that Docetaxel Kabi be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Docetaxel Kabi odobri dovoljenje za promet.
Therefore, the CHMP's view was that, as for Taxotere, the benefit outweighs the identified risk. 
Zato je menil, da njegove koristi, tako kot pri zdravilu Taxotere, odtehtajo znana tveganja.
It can also be used with cisplatin (another anticancer medicine) in patients who have not yet received any treatment for their cancer; 
Uporablja se lahko tudi v kombinaciji s cisplatinom (drugim zdravilom proti raku) pri bolnikih, ki se zaradi raka še niso zdravili;
The active substance in Docetaxel Kabi, docetaxel, belongs to the group of anticancer medicines known as the taxanes. 
Zdravilna učinkovina zdravila Docetaxel Kabi, docetaksel, spada v skupino zdravil proti raku, imenovanih taksani.
The company also showed that the Docetaxel Kabi solution for infusion has comparable quality to that of Taxotere. 
Poleg tega je predstavila tudi dokaze o tem, da je raztopina za infundiranje zdravila Docetaxel Kabi primerljive kakovosti kot zdravilo Taxotere.
Docetaxel Kabi is used with prednisone or prednisolone (anti-inflammatory medicines); 
Zdravilo Docetaxel Kabi se uporablja sočasno s prednizonom ali prednizolonom (protivnetnima zdraviloma);
Docetaxel Kabi is a medicine that contains the active substance docetaxel. 
Docetaxel Kabi je zdravilo, ki vsebuje zdravilno učinkovino docetaksel.
Why has Docetaxel Kabi been approved? 
Zakaj je bilo zdravilo Docetaxel Kabi odobreno?
• head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread). 
• raka glave in vratu pri bolnikih, katerih rak je lokalno napredoval (rakava tvorba je zrasla, vendar se še ni razširila po telesu).Zdravilo Docetaxel Kabi se uporablja v kombinaciji s cisplatinom in 5-fluoroacilom.
No additional studies were needed as Docetaxel Kabi is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Taxotere. 
Ker je zdravilo Docetaxel Kabi generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Taxotere, niso bile potrebne nobene dodatne študije.
What is Docetaxel Kabi used for? 
Za kaj se zdravilo Docetaxel Kabi uporablja?
What is Docetaxel Kabi? 
Kaj je zdravilo Docetaxel Kabi?
How has Docetaxel Kabi been studied? 
Kako je bilo zdravilo Docetaxel Kabi raziskano?
Docetaxel Kabi is used with cisplatin and 5-fluorouracil (other anticancer medicines); 
• adenokarcinoma želodca (vrste želodčnega raka) pri bolnikih, ki se zaradi raka še niso zdravili.Zdravilo Docetaxel Kabi se uporablja v kombinaciji s cisplatinom in 5-fluoroacilom (drugima zdraviloma proti raku);
How does Docetaxel Kabi work? 
Kako zdravilo Docetaxel Kabi deluje?